Acceptance Limits for the New ICH USP 29 Content-Uniformity Test - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Acceptance Limits for the New ICH USP 29 Content-Uniformity Test
Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.

Pharmaceutical Technology

Where k = 2.4 for n = 10; k = 2.0 for n = 30; s is the standard deviation of the observations.

Unless otherwise specified, all the measurements of dosage units and criteria values (such as L 1) are in percentage label claim.

Lower probability bound of passing USP

Notice that P(passing USP test)

Assume that the X i 's follow a normal distribution denoted N (μ, σ). Then the values of P(S 1) and P(S 2) can be calculated as described in the following two subsections.

Computation of P(S 1)

Given the definition of AV, it can be seen that:

For T ≤ 101.5

The density function of Z 2 is a x2 distribution with n – 1 degrees of freedom and is denoted as x2 (n – 1).

The joint density function is f(z 1,Z 2) = f 1(z 1) f 2(Z 2),

Given the independence of z 1 and Z 2, P(S 1) can be rewritten in terms of z 1 and Z 2 as:

Computation of P(S 2)

There are two subcriteria in S 2, which are denoted as C 21 and C 22, respectively, as follows:

C 21 = AV of the 30 dosage units is less than or equal to L 1.

C 22 = no unit deviates from the calculated value of M by more than 25% of M.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here